HLS Therapeutics (HLS) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
14 May, 2026Opening remarks and agenda
Meeting opened with a welcome and instructions for virtual participation, including Q&A and voting procedures.
Forward-looking statements disclaimer was read, highlighting risks and uncertainties.
Agenda included presentation of financial statements, election of directors, and reappointment of auditor.
Board and executive committee updates
Introduction of attending officers and nominees for director positions.
Eight nominees for director positions were named and confirmed as present.
Shareholder proposals
No additional nominations for directors were accepted due to advance notice provisions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from HLS Therapeutics
- Cardiovascular net sales up 25% year-over-year; 2026 guidance reaffirmed.HLS
Q2 2026 - All resolutions, including Director elections and incentive plan approval, passed at the virtual AGM.HLSAGM 2026
- Growth driven by new cardiovascular launches, strong financials, and expanding market access.HLSInvestor presentation
- Q1 2026 saw revenue and cash growth, NILEMDO's strong launch, and reaffirmed 2026 guidance.HLSQ1 2026
- All directors were elected and the auditor reappointed, with all motions passing by shareholder vote.HLSAGM 2024
- Strong financials and new cardiovascular launches position for accelerated growth post-2026.HLSCorporate presentation
- EBITDA up 18%, cash flow doubled, Vascepa gains, NILEMDO launch, and net debt reduced.HLSQ4 2025
- Adjusted EBITDA up 25% YTD, cash from operations up 121%, and debt reduced.HLSQ3 2025
- Q1 2025 delivered 5% revenue growth, higher EBITDA, and new cardiovascular portfolio expansion.HLSQ1 2025